All News

antibody (Keep)

The Potential of Rituximab Efficacy in Systemic Sclerosis

d Jack Cush, MD

Rituximab (RTX) has been in the news a lot lately; more surprisingly for its potential benefits in progressive systemic sclerosis (SSc).

Ebata and colleagues have published the results of a double-blind, randomised, placebo-controlled trial comparing intravenous RTX to placebo in 56 SSc patients. Patients had to have a modified Rodnan Skin Score (mRSS) of 10 or more. The primary endpoint was the change in mRSS at 24 weeks. 

Read Article
infusion.biologic.jpg

ACR Stands Against Insurer Mandated Infusion Locations

d ACR

The American College of Rheumatology (ACR) has released an updated position statement on patient safety and site of service for biologics outlining several reasons why the ACR strongly believes infusions should be administered in a monitored health care setting with onsite supervision by a provid

Read Article
RheumNow Podcast square

RheumNow Podcast – Modern Treatment of RA Pregnancy (6.25.2021)

d Jack Cush, MD

Dr. Jack Cush reviews this week’s news and journal reports featured on RheumNow.com.

Read Article
party, adult, birthday, mardi

Birthday Gatherings Increase COVID-19 Risk

d Jack Cush, MD

How risky are family gatherings, birthday parties and informal social gatherings? A cross-sectional analysis suggests that birthdays may be associated with increased rates of COVID-19 infection within households where there is a high COVID-19 prevalence in the population. 

Read Article
106-0674_IMG.JPG

Knee Replacement in Obese OA is Cost Effective

d Jack Cush, MD

Debates over ideal candidates for total knee replacement (TKR) in osteoarthritis patients often excludes those who are obese, but a recent article in the Annals of Internal Medicine suggests that TKR is both effective and cost-effective in obese patients (BMI >40 kg/m2) with

Read Article
Analysis of Ph 3 data Tofacitinib in Ulcerative Colitis shows no increase in Cancer; rates equal to that seen w/ Tofa in RA, PsA & other biologics in UC. In 1124 pts (2576 PtYrs) there were 20 cancers, excluding NMSC (IR, 0.75; 0.46–1.16) https://t.co/xiTIKYAtyY

Links:

Dr. John Cush RheumNow ( View Tweet)

Blindness with Tocilizumab in GCA: Is it a Worry? https://t.co/PJYap294jm https://t.co/q1izGlH68j

Links:

Dr. John Cush RheumNow ( View Tweet)
EULAR 2021 Lupus Panel Drs. Cush, Dao, Pope, Dein and Yusof discuss a number of lupus presentations as well as abstracts presented at the virtual EULAR 2021 meeting. Lupus nephritis and treat-to-remission presentations were discussed by the panel. https://t.co/yUEXTOatpR

Links:

Dr. John Cush RheumNow ( View Tweet)

Alcohol abuse worsens psoriasis. Prospective study of 266 Psoriasis pts (1/2 biologics; 1/2 ; conventional Rx). Poorer outcomes predicted by alcohol abuse (CAGE score) (regression co-efficient 1.40), obesity (1.84) & conventional Rx (4.39) https://t.co/CJGTT0HoV2

Links:

Dr. John Cush RheumNow ( View Tweet)

Which patients with psoriasis are at risk to develop PsA? https://t.co/5sj5HSnke3 https://t.co/vxOHIUrevd

Links:

Dr. John Cush RheumNow ( View Tweet)
FDA has granted emergency use authorization (EUA) for Actemra (tocilizumab) us in treating hospitalized COVID-19 (adults and kids) patients on steroids and who require, supplemental oxygen, mechanical ventilation, or ECMO https://t.co/YAVfbykcti https://t.co/d7pS1lUXpa

Links:

Dr. John Cush RheumNow ( View Tweet)
The FDA has informed Abbvie that their supplemental application for new indications (PsA and AS) for upadacitinib (Rinvoq) has been delayed; the FDA citing its ongoing review of tofacitinibs safety concerns stemming from the ORAL Surveillance RA study https://t.co/sSJyVtQNYu

Links:

Dr. John Cush RheumNow ( View Tweet)

Danish population study shows that all cause mortality in GCA is increased 49%,(RR 1.49; CI1.36-1.64) after 1 year but less so at 10 years (RR 1.03: 1.00-1.05). Deaths usually due to infectious, endocrine, cardiovascular, GI diseases https://t.co/p36zDskf6y

Links:

Dr. John Cush RheumNow ( View Tweet)

RHEUMATOLOGIST SURVEY - on Osteoporosis, Osteomalacia and a Family Hx of recurrent Fractures - Answer a 4 question survey here >> https://t.co/TuY1fXAAk5

Links:

Dr. John Cush RheumNow ( View Tweet)

Guidelines for the prevention, diagnosis and treatment of Lyme disease have been formulated by the ACR, Infectious Diseases Society of America and the American Academy of Neurology https://t.co/RgHzCLrtDM

Links:

Dr. John Cush RheumNow ( View Tweet)

The Swedish Rheumatology Quality Register looked at risk of ant.uveitis (AU). From 4851 starting secukinumab (456) or TNFinhibitor (4395 ), there was higher AU risk w/ SEC (adj HR 2.32; 1.16-4.63) & ETN (1.82;1.13-2.93) (ADA as referent) https://t.co/j06MtKedYU

Links:

Dr. John Cush RheumNow ( View Tweet)

Metanalysis shows no clear association between allopurinol use and a lowered all-cause mortality in gout patients, but the number of studies was small https://t.co/MM0nIjZPbV

Links:

Dr. John Cush RheumNow ( View Tweet)

Italian survey foud 82% of MSK healthcare workers willing to receive COVID-19 vaccine, but only 55% of their rheumatic Dz patients were as willing, even if they perceived they were at risk. Not out of fear or distrust. more education needed https://t.co/nPhhME2dnC

Links:

Dr. John Cush RheumNow ( View Tweet)

66 yoF w/ prurtitic rash, weakness, SOB, hyperpigmented papules over knuckles, periungual hemorrhages, shawl like rash and the Holster sign (lateral thighs). Which drugs would you use: A. Steroids B. IVIG C. MMF D. Baricitinib E. Plasmapheresis https://t.co/IA4qbGri5b

Links:

Dr. John Cush RheumNow ( View Tweet)

Is there a connection between stress and the onset of RA? https://t.co/Oir9ZV3m7i https://t.co/GTpvTCiMAP

Links:

Dr. John Cush RheumNow ( View Tweet)
×